Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies

Daoud, Safa; Alabed, Shada J.; Dahabiyeh, Lina A.

doi:10.2478/acph-2021-0016

References

1. N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu and P. Niu, A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med. 382 (2020) 727–733; https://doi.org/10.1056/NEJMoa200101710.1056/NEJMoa2001017709280331978945
Search in Google Scholar Back to article
2. A. Zumla, J. F. Chan, E. I. Azhar, D. S. Hui and K. Y Yuen, Coronaviruses—drug discovery and therapeutic options, Nat. Rev. Drug Discov. 15 (2016) 327–347; https://doi.org/10.1038/nrd.2015.3710.1038/nrd.2015.37709718126868298
Search in Google Scholar Back to article
3. F. He, Y. Deng and W. Li, Coronavirus Disease 2019 (COVID-19): What we know? J. Med. Virol. (2020) (7 pages); https://doi.org/10.1002/jmv.2576610.1002/jmv.25766722834032170865
Search in Google Scholar Back to article
4. C. C. Lai, T. P. Shih, W. C. Ko, H. J. Tang and P. R. Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int. J. Antimicrob. Agents55 (2020) Article ID 105924; https://doi.org/10.1016/j.ijantimicag.2020.10592410.1016/j.ijantimicag.2020.105924712780032081636
Search in Google Scholar Back to article
5. J. She, J. Jiang, L. Ye, L. Hu, C. Bai and Y. Song, 2019 Novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies, Clin.. Transl. Med.9 (2020) Article ID 19; https://doi.org/10.1186/s40169-020-00271-z10.1186/s40169-020-00271-z703326332078069
Search in Google Scholar Back to article
6. World Health Organization, Novel Coronavirus (Covid-19): Situation Report, 3. 2020, WHO, Geneve 2020; https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=CjwKCAjwq832BRA5EiwACvCWsSQ_-qAh4z8Z5_gvnayDI2PrSx4poydPpu-pvDZX-k34RQDqn8TgEBoChdkQA-vD_BwE; last access date May 31, 2020
Search in Google Scholar Back to article
7. H. A. Rothan and S. N. Byrareddy, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak, J. Autoimmun.109 (2020) Article ID 102433 (4 pages); https://doi.org/10.1016/j.jaut.2020.10243310.1016/j.jaut.2020.102433712706732113704
Search in Google Scholar Back to article
8. S. L. Senanayake, Drug repurposing strategies for COVID-19, Future Drug Discov.2 (2020) (3 pages); https://doi.org/10.4155/fdd-2020-001010.4155/fdd-2020-0010
Search in Google Scholar Back to article
9. S. Pushpakom, F. Iorio, P. A. Eyers, K. J. Escott, S. Hopper, A. Wells, A. Doig, T. Guilliams, J. Latimer, C. McNamee and A. Norris, Drug repurposing: progress, challenges and recommendations, Nat. Rev. Drug Discov. 18 (2019) 41–58; https://doi.org/10.1038/nrd.2018.16810.1038/nrd.2018.16830310233
Search in Google Scholar Back to article
10. S. G. V. Rosa and W. C. Santos, Clinical trials on drug repositioning for COVID-19 treatment, Rev. Panam. Salud Públ. 44 (2020) e40; https://doi.org/10.26633/RPSP.2020.4010.26633/RPSP.2020.40710528032256547
Search in Google Scholar Back to article
11. A. Gaurav, V. Gautam, S. Pereira, J. Alvarez-Leite, F. Vetri, M. Choudhury, D. Pelligrino, P. Sundivakkam, K. Radhakrishnan and A. Krieger, Structure-based three-dimensional pharmacophores as an alternative to traditional methodologies, J. Receptor Ligand Channel Res.7 (2014) 27–38; https://doi.org/10.2147/JRLCR.S4684510.2147/JRLCR.S46845
Search in Google Scholar Back to article
12. M. P. Sanders, R. McGuire, L. Roumen, I. J. de Esch, J. de Vlieg, J. P. Klomp and C. de Graaf, From the protein’s perspective: the benefits and challenges of protein structure-based pharmacophore modeling, MedChemComm.3 (2012) 28–38; https://doi.org/10.1039/C1MD00210D10.1039/C1MD00210D
Search in Google Scholar Back to article
13. M. Wieder, U. Perricone, T. Seidel, S. Boresch and T. Langer, Comparing pharmacophore models derived from crystal structures and from molecular dynamics simulations, Monatsh. Chem. 147 (2016) 553–563, https://doi.org/10.1007/s00706-016-1674-110.1007/s00706-016-1674-1
Search in Google Scholar Back to article
14. M. Arooj, S. Sakkiah, S. Kim, V. Arulalapperumal and K. W. Lee, A combination of receptor-based pharmacophore modeling & QM techniques for identification of human chymase inhibitors. PLoS One8 (2013) e63030; https://doi.org/10.1371/journal.pone.006303010.1371/journal.pone.0063030
Search in Google Scholar Back to article
15. Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, B. Zhang, X. Li, L. Zhang, C. Peng, Y. Duan, J. Yu, L. Wang, K. Yang, F. Liu, R. Jiang, X. Yang, T. You, X. Liu, X. Yang, F. Bai, H. Liu, X. Liu, L. W. Guddat, W. Xu, G. Xiao, C. Qin, Z. Shi, H. Jiang, Z. Rao and H. Yang: Structure of Mpro from SARSCoV-2 and discovery of its inhibitors, Nature5 (2020) (20 pages); https://doi.org/10.1038/s41586-020-2223-y10.1038/s41586-020-2223-y
Search in Google Scholar Back to article
16. L. A. Dahabiyeh, E. Y. Abu-rish and M. O. Taha, Inhibition of monoglyceride lipase by proton pump inhibitors: investigation using docking and in vitro experiments, Pharmacol. Rep.72 (2019) 435–442; https://doi.org/10.1007/s43440-019-00013-010.1007/s43440-019-00013-0
Search in Google Scholar Back to article
17. L. A. Dahabiyeh, Y. Bustanji and M. O. Taha, The herbicide quinclorac as potent lipase inhibitor: Discovery via virtual screening and in vitro/in vivo validation, Chem. Biol. Drug Des. 93 (2019) 787–797; https://doi.org/10.1111/cbdd.1346310.1111/cbdd.13463
Search in Google Scholar Back to article
18. D. J. Diller and K. M. Merz, Jr, High throughput docking for library design and library prioritization, Proteins43 (2001) 113–124; https://doi.org/10.1002/1097-0134(20010501)43:2<113::aidprot1023>3.0.co;2-t
Search in Google Scholar Back to article
19. S. N. Rao, M. S. Head, A. Kulkarni and J. M. LaLonde, Validation studies of the site-directed docking program LibDock, J. Chem. Inf. Model.47 (2007) 2159–2171; https://doi.org/10.1021/ci600429910.1021/ci6004299
Search in Google Scholar Back to article
20. A. N. Jain, Scoring noncovalent protein-ligand interactions: a continuous differentiable function tuned to compute binding affinities, J. Comput. Aided Mol. Des.10 (1996) 427–440; https://doi.org/10.1007/BF0012447410.1007/BF00124474
Search in Google Scholar Back to article
21. A. Krammer, P. D. Kirchhoff, X. Jiang, C. Venkatachalam and M. Waldman, LigScore: a novel scoring function for predicting binding affinities, J. Mol. Graph. Model. 23 (2005) 395–407; https://doi.org/10.1016/j.jmgm.2004.11.00710.1016/j.jmgm.2004.11.007
Search in Google Scholar Back to article
22. C. M. Venkatachalam, X. Jiang, T. Oldfield and M. Waldman, LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites, J. Mol. Graph. Model. 21 (2003) 289–307; https://doi.org/10.1016/s1093-3263(02)00164-x10.1016/S1093-3263(02)00164-X
Search in Google Scholar Back to article
23. D. K. Gehlhaar, D. Bouzida and P. A. Rejto, Reduced dimensionality in ligand-protein structure prediction: covalent inhibitors of serine proteases and design of site-directed combinatorial libraries, ACS Pub.719 (1999); https://doi.org/10.1021/bk-1999-0719.ch01910.1021/bk-1999-0719.ch019
Search in Google Scholar Back to article
24. I. Muegge, PMF scoring revisited, J. Med. Chem. 49 (2006) 5895–5902; https://doi.org/10.1021/jm050038s10.1021/jm050038s17004705
Search in Google Scholar Back to article
25. I. Muegge and Y. C. Martin, A general and fast scoring function for protein-ligand interactions: a simplified potential approach, J. Med. Chem. 42 (1999) 791–804; https://doi.org/10.1021/jm980536j10.1021/jm980536j10072678
Search in Google Scholar Back to article
26. J. Wang, Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study, J. Chem. Inf. Model. (2020) (10 pages); https://doi.org/10.1021/acs.jcim.0c0017910.1021/acs.jcim.0c00179719797232315171
Search in Google Scholar Back to article
27. A. Farag, P. Wang, M. Ahmed and H. Sadek, Identification of FDA approved drugs targeting COVID-19 virus by structure-based drug repositioning, ChemRxiv. (preprint) (2020); https://doi.org/10.26434/chemrxiv.12049647.v110.26434/chemrxiv.12049647.v1
Search in Google Scholar Back to article
28. A. D. Mesecar (Center for Structural Genomics of Infectious Diseases, CSGID), A taxonomically-driven approach to development of potent, broad-spectrum inhibitors of coronavirus main pro-tease including SARS-CoV-2 (COVID-19), to be published; PDB ID 6W63, title: Structure of COVID-19 main protease bound to potent broad-spectrum non-covalent inhibitor X77, 2020; https://doi.org/10.2210/pdb6W63/pdb10.2210/pdb6w63/pdb
Search in Google Scholar Back to article
29. J. Meslamani and D. Rognan, Protein-ligand pharmacophores: concept, design and applications, CICSJ Bull. 33 (2015) 27–32; https://doi.org/10.11546/cicsj.33.27
Search in Google Scholar Back to article
30. L. Dong, S. Hu and J. Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov. Ther.14 (2020) 58–60; https://doi.org/10.5582/ddt.2020.0101210.5582/ddt.2020.0101232147628
Search in Google Scholar Back to article
31. E. P. Tchesnokov, J. Y. Feng, D. P. Porter and M. Götte, Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir, Viruses11 (2019) Article ID 326; https://doi.org/10.3390/v1104032610.3390/v11040326652071930987343
Search in Google Scholar Back to article
32. J. A. Al-Tawfiq, A. H. Al-Homoud and Z. A. Memish, Remdesivir as a possible therapeutic option for the COVID-19, Travel. Med. Infect. Dis.34 (2020) Article ID 101615; https://doi.org/10.1016/j.tmaid.2020.10161510.1016/j.tmaid.2020.101615712939132145386
Search in Google Scholar Back to article
33. T. Stanković, J. Dinić, A. Podolski-Renić, L. Musso, S. S. Burić, S. Dallavalle and M. Pešić, Dual inhibitors as a new challenge for cancer multidrug resistance treatment, Curr. Med. Chem.26 (2019) 6074–6106; https://doi.org/10.2174/092986732566618060709485610.2174/092986732566618060709485629874992
Search in Google Scholar Back to article
34. A. Chandwani and J. Shuter, Lopinavir/ritonavir in the treatment of HIV-1 infection: a review, Ther. Clin. Risk Manag. 4 (2008) 1023–1033; https://doi.org/10.2147/tcrm.s328510.2147/TCRM.S3285
Search in Google Scholar Back to article
35. J. Dorward and K. Gbinigie, Lopinavir/ritonavir: A rapid review of effectiveness in COVID-19 (on behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine-CEBM); https://www.cebm.net/covid-19/lopinavir-ritonavir-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid/; last access date April 14, 2020
Search in Google Scholar Back to article
36. B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, L. Ruan, B Song, Y. Cai, M. Wei, X. Li, J. Xia, N. Chen, J. Xiang, T. Yu, T. Bai, X. Xie, L. Zhang, C. Li, Y. Yuan, H. Chen, H. Li, H. Huang, S. Tu, F. Gong, Y. Liu, Y. Wei, C. Dong, F. Zhou, X. Gu, J. Xu, Z. Liu, Y. Zhang, H. Li, L. Shang, K. Wang, K. Li, X. Zhou, X. Dong, Z. Qu, S. Lu, X. Hu, S. Ruan, S. Luo, J. Wu, L. Peng, F. Cheng, L. Pan, J. Zou, C. Jia, J. Wang, X. Liu, S. Wang, X. Wu, Q. Ge, J. He, H. Zhan, F. Qiu, L. Guo, C. Huang, T. Jaki, F. G. Hayden, P. W. Horby, D. Zhang and C. Wang, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N. Engl. J. Med. 382 (2020) 1787–1799; https://doi.org/10.1056/NEJMoa200128210.1056/NEJMoa2001282712149232187464
Search in Google Scholar Back to article

Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies

References

Paradigm

My account